Biotech marketing fails when it picks a side.
The clinical-blue-gradient school treats science as authority. The warm-photography school treats it as feeling. Both are wrong. Biotech only works when both are true at once. The molecule and the mother. The mechanism and the meaning. We design that simultaneity.
For three decades, we have watched biotech brands spend millions to look indistinguishable from one another. Same gradient. Same handshake photograph. The same single word used six times in a homepage hero.
We do something else. We treat your brand the way your science treats a hypothesis: with rigor, with specificity, and with the humility to throw out anything that does not survive contact with evidence.
The result is brand work that earns the trust of physicians, the attention of investors, and (when the campaign demands it) the participation of the patients who need your trial to enroll.
325 Editorial Standards / Section 2.1Evidence.
From the Practice
A women's health brand, elevated.
Evofem held the science. They needed a brand that could hold the conversation. We rebuilt the visual system around education, agency, and trust, then shipped a digital experience that respected the patient's intelligence.
Inhaled therapeutics, made legible.
Brand identity, narrative video, and educational systems for a company building inhaled biologics. We translated mechanism into metaphor without losing the underlying truth.
A brand built to raise capital.
Aspargo came to us pre-funding. We built the identity that helped them tell the story to the people who write the checks.
One company. Two audiences.
A diagnostics company speaking to clinicians and to patients. We architected two identities under one strategy (Synaps DX and DISCERN™) so neither audience was diluted.
From unknown to listed.
Brand awareness from zero, plus the IR materials that carried Tyme through their NASDAQ transition.
A second listing. A second voice.
Angion's science had matured. Their brand had not. We expanded the visual and narrative system to match the company's clinical ambition, then carried it through the NASDAQ transition with IR-grade rigor.
"The weight is over." Three words. A category.
A GLP-1 era consumer health brand that needed to compete with the loudest category in pharma without joining the noise. We built a brand voice that was confident enough to be quiet, and a campaign system that earned attention by withholding it.
A digital campaign we built for a clinical trial enrolled the entire patient cohort in under two months. Most agencies pitch six. We measured ours in weeks because the science was waiting.
325 / Patient Recruitment / Case File 09What we refuse to do.
Every category accumulates clichés. Biotech has accumulated more than most. We start every engagement by listing what your competitors are doing, and committing, in writing, never to do those things on your behalf.
- 01. Backgrounds of disembodied DNA helices.
- 02. The phrase "revolutionary breakthrough."
- 03. Cyan-to-white pharmaceutical gradients.
- 04. Stock photography of hands meeting in agreement.
- 05. Smiling lab technicians holding clipboards.
- 06. Hexagonal pattern systems pretending to be molecules.
- 07. "Innovative" as a substitute for the actual mechanism.
- 08. Investor decks with seventeen shades of blue.
The protocol.
Audit
We read every clinical document, every investor deck, every press release. We interview the founders, the CMO, the head of regulatory. We don't pitch ideas until we understand what your science actually is.
Position
We define the brand strategy in plain English: who you are, who you serve, what you refuse to be confused with. One page. Defensible against every other brand in your category.
Build
Identity system, voice, web architecture, IR materials, patient-facing assets, medical-education collateral. Designed by humans, reviewed by clinicians, tested with the audiences they're meant for.
Measure
Every engagement ends with a measurement protocol. Trial enrollment. Investor inbound. Physician opt-ins. We instrument what matters so the next engagement starts with data, not intuition.
- 01
Brand strategy & identity systems
Applied toEvofem / Aspargo / Aerami - 02
Investor relations & NASDAQ transitions
Applied toTyme / Angion - 03
Patient recruitment campaigns
Applied toClinical Trial / 8 wks to enroll - 04
Medical education & print logistics
Applied toPharma practice / 30+ projects - 05
Narrative video & educational film
Applied toAerami Therapeutics - 06
Multi-brand architecture
Applied toSynaps DX / DISCERN™ - 07
DTC consumer health positioning
Applied toMelt RX
Biotech audiences can tell when you're hiding behind adjectives. We design as if they can read.
325 / Editorial StandardsBegin the conversation.
Every engagement begins with a sixty-minute call. No deck. No pitch theater. We ask about your science, your audiences, and what your last agency got wrong. If we're a fit, we'll send a scoped proposal within the week.